Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEPANC-1: IMM-101 plus SBRT in limited metastatic pancreatic cancer
NL-OMON58985Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of IMM-101 in pancreatic cancer (PC) (2 arms), sponsored by Erasmus MC. Primary endpoints: Safety and toxicity of IMM-101 combined with SBRT and Efficacy of IMM-101 combined with SBRT. Started Feb 2021; status: completed.
02
Drugs
IMM-101
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON58985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58985.